MBX Biosciences, Inc. (MBX) Stock Forecast & Price Target

Compare

197 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MBX Analyst Ratings

Moderate Buy

6 Buy

0 Hold

1 Sell

Based on 7 analysts giving stock ratings to

MBX

Biosciences, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MBX Stock 12 Month Forecast

Average Price Target

$59.19

▲(91.55% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for MBX Biosciences, Inc. in the last 3 months. The average price target is $59.19 with a high forecast of $80.00 and a low forecast of $31.97. The average price target represents a 91.55% change from the last price of $30.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","24":"$24","43":"$43","62":"$62","81":"$81"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$59.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,24,43,62,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,36.61538461538461,40.23076923076923,43.84615384615385,47.46153846153846,51.07692307692308,54.69230769230769,58.30769230769231,61.92307692307692,65.53846153846155,69.15384615384616,72.76923076923077,76.38461538461539,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,35.01461538461538,37.02923076923077,39.043846153846154,41.058461538461536,43.073076923076925,45.08769230769231,47.10230769230769,49.11692307692307,51.13153846153846,53.146153846153844,55.16076923076923,57.175384615384615,{"y":59.19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,32.92076923076923,32.84153846153846,32.762307692307694,32.683076923076925,32.603846153846156,32.52461538461539,32.44538461538461,32.36615384615384,32.286923076923074,32.207692307692305,32.128461538461536,32.04923076923077,{"y":31.97,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$59.19

Lowest Price Target$31.97

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Annabel Samimy

Stifel Nicolaus

$45→$50

Buy

61.81%

Upside

Reiterated

12/19/25

MBX Biosciences price target raised to $50 from $45 at StifelMBX Biosciences price target raised to $50 from $45 at Stifel

Srikripa Devarakonda

Truist Financial

Buy

―

Reiterated

12/05/25

Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (NASDAQ: MBX), Praxis Precision Medicines (NASDAQ: PRAX) and Iovance Biotherapeutics (NASDAQ: IOVA)

Seamus Fernandez

Guggenheim

$77

Buy

149.19%

Upside

Reiterated

12/04/25

MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim

Corinne Johnson

Goldman Sachs

$31.97

Sell

3.46%

Upside

Initiated

12/04/25

MBX Biosciences initiated with a Sell at Goldman SachsMBX Biosciences initiated with a Sell at Goldman Sachs

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/13/25

MBX Biosciences, Inc.: Strong Financial Outlook and Strategic Direction Support Buy Rating

Trevor Allred

Oppenheimer

$38→$80

Buy

158.90%

Upside

Reiterated

11/07/25

MBX Biosciences, Inc. (MBX) Gets a Buy from Oppenheimer

Uy Ear

Mizuho Securities

$56→$57

Buy

84.47%

Upside

Reiterated

11/06/25

MBX Biosciences, Inc. (MBX) Receives a Buy from Mizuho Securities

Jonathan Wolleben

Citizens JMP

$38→$61

Buy

97.41%

Upside

Reiterated

09/22/25

MBX Biosciences price target raised to $61 from $38 at Citizens JMPMBX Biosciences price target raised to $61 from $38 at Citizens JMP

Roger Song

Jefferies

$35→$36

Buy

16.50%

Upside

Initiated

08/15/25

MBX Biosciences assumed with a Buy at JefferiesMBX Biosciences assumed with a Buy at Jefferies

Jessica Fye

J.P. Morgan

Buy

―

Reiterated

06/16/25

Strategic Growth and Clinical Advancements Propel MBX Biosciences to a Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Annabel Samimy

Stifel Nicolaus

$45→$50

Buy

61.81%

Upside

Reiterated

12/19/25

MBX Biosciences price target raised to $50 from $45 at StifelMBX Biosciences price target raised to $50 from $45 at Stifel

Srikripa Devarakonda

Truist Financial

Buy

―

Reiterated

12/05/25

Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (NASDAQ: MBX), Praxis Precision Medicines (NASDAQ: PRAX) and Iovance Biotherapeutics (NASDAQ: IOVA)

Seamus Fernandez

Guggenheim

$77

Buy

149.19%

Upside

Reiterated

12/04/25

MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim

Corinne Johnson

Goldman Sachs

$31.97

Sell

3.46%

Upside

Initiated

12/04/25

MBX Biosciences initiated with a Sell at Goldman SachsMBX Biosciences initiated with a Sell at Goldman Sachs

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/13/25

MBX Biosciences, Inc.: Strong Financial Outlook and Strategic Direction Support Buy Rating

Trevor Allred

Oppenheimer

$38→$80

Buy

158.90%

Upside

Reiterated

11/07/25

MBX Biosciences, Inc. (MBX) Gets a Buy from Oppenheimer

Uy Ear

Mizuho Securities

$56→$57

Buy

84.47%

Upside

Reiterated

11/06/25

MBX Biosciences, Inc. (MBX) Receives a Buy from Mizuho Securities

Jonathan Wolleben

Citizens JMP

$38→$61

Buy

97.41%

Upside

Reiterated

09/22/25

MBX Biosciences price target raised to $61 from $38 at Citizens JMPMBX Biosciences price target raised to $61 from $38 at Citizens JMP

Roger Song

Jefferies

$35→$36

Buy

16.50%

Upside

Initiated

08/15/25

MBX Biosciences assumed with a Buy at JefferiesMBX Biosciences assumed with a Buy at Jefferies

Jessica Fye

J.P. Morgan

Buy

―

Reiterated

06/16/25

Strategic Growth and Clinical Advancements Propel MBX Biosciences to a Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MBX Biosciences, Inc.

1 Month

xxx

Success Rate

3/3 ratings generated profit

Average Return

+25.80%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +25.80% per trade.

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+109.77%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +109.77% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

3/3 ratings generated profit

Average Return

+203.40%

reiterated a buy rating 3 months ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +203.40% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+203.40%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +203.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MBX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MBX has received 13 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. MBX average Analyst price target in the past 3 months is 59.19.

Each month's total comprises the sum of three months' worth of ratings.

MBX Financial Forecast

MBX Earnings Forecast

Next quarter’s earnings estimate for MBX is -$0.67 with a range of -$0.84 to -$0.46. The previous quarter’s EPS was -$0.63. MBX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MBX has Performed in-line its overall industry.

No data currently available

MBX Sales Forecast

Next quarter’s sales forecast for MBX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MBX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MBX has Performed in-line its overall industry.

MBX Stock Forecast FAQ

What is MBX’s average 12-month price target, according to analysts?

Based on analyst ratings, MBX Biosciences, Inc.’s 12-month average price target is 59.19.

What is MBX’s upside potential, based on the analysts’ average price target?

MBX Biosciences, Inc. has 91.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MBX a Buy, Sell or Hold?

MBX Biosciences, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 0 hold ratings and 1 sell ratings.

What is MBX Biosciences, Inc.’s price target?

The average price target for MBX Biosciences, Inc. is 59.19. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $31.97. The average price target represents 91.55% Increase from the current price of $30.9.

What do analysts say about MBX Biosciences, Inc.?

MBX Biosciences, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of MBX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

MBX Biosciences, Inc. (MBX) Stock Forecast & Price Target

MBX Analyst Ratings

MBX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MBX Biosciences, Inc.

MBX Analyst Recommendation Trends

MBX Financial Forecast

MBX Earnings Forecast

MBX Sales Forecast

MBX Stock Forecast FAQ

Detailed List of Analyst Forecasts